TORONTO, ON--(Marketwired - Dec 14, 2016) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce that its partner BMV Medica SA de C.V. through its host company Ackerman Pharma, has signed a Sales & Marketing Agreement with Gedeon Richter Mexico S.A.P.I. de C.V. a Mexican-based company and affiliate of Gedeon Richter Plc, for Easton / BMV's "Gynofit" Lactic Acid Gel for the treatment of Bacterial Vaginosis in Mexico. http://www.richter.hu/en-US/Pages/default.aspx
The sales and marketing agreement is for the country of Mexico, a pharmaceutical market representing almost 40% of Latin America, possessing double-digit annual growth rates. Marketing and Sales of "Gynofit" are expected to commence In February of 2017. "This Agreement is instrumental for Easton / BMV's Latin American growth plans." Mr. Evan Karras, CEO of Easton Pharmaceuticals stated. Mr. Karras further commented, "This represents a strong strategic relationship for Easton / BMV as Gedeon Richter Plc and its affiliate company, Mexico S.A.P.I de C.V. is a premier international pharmaceutical company focused on Women's Health, with a presence in more than 38 countries with 5 manufacturing facilities, 29 representative offices, 38 commercial subsidiaries and wholesale companies employing approximately 1000 people. This agreement adds to our previous distribution agreement announcement for Central America and the Dominican Republic for our exclusive Women's Heath line of products. We will continue to increase our distribution channels and sales opportunities in other territories for Gynofit and our patented, licensed and exclusive VagiSan (VS-Sense) and AmnioSense (AL-Sense) line of products."
"Gynofit" is a natural product treatment for women who are diagnosed with BV (Bacterial Vaginosis), a condition that affects nearly all women at some point in their lives and is one of the most common reasons for gynecological visits by women. In addition, Gynofit will be promoted for help in maintenance of a healthy vaginal flora. The agreement with Gedeon Richter Mexico S.A.P.I de C.V. provides for setting annual minimums in return for granting exclusivity. Gedeon Richter Plc and Gedeon Richter Mexico S.A.P.I. de C.V. has committed to a strong marketing support for Gynofit, which Easton believes will steadily drive sales in Mexico over the next three years and beyond.
The agreement with Gedeon Richter Mexico S.A.P.I . de C.V. for "Gynofit" is separate from Easton / BMV's other patented and exclusive diagnostic products (VagiSan (VS-Sense) & AmnioSense (AL-Sense) for which Easton is currently in separate late stage negotiations with large multi-national pharmaceutical companies.
In other developments, Easton Pharmaceuticals has entered into and are in late stage negotiations with BMV Medica SA de C.V. to acquire all of BMV and its assets. In addition, Easton is in late stage negotiations for an international medical marijuana initiative and to acquire a profitable and steadily growing Vaporizer company with their own line of manufactured and proprietary e-liquids and accessories, possessing growing international sales. News updates to be made available as they develop.
For More Detailed Information on Gedeon Richter Plc Visit:
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products from CommonSense Of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine's Ontario, Canada.
For More Information Visit:
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope," "positive," "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.